Top Markets
Coin of the day
Marinus Pharmaceuticals, Inc. Marinus Pharmaceuticals, Inc.

Marinus Pharmaceuticals, Inc.

MRNS
주식 순위 #28050
Marinus Pharmaceuticals, Inc. is a specialized biopharmaceutical firm dedicated... Marinus Pharmaceuticals, Inc. is a specialized biopharmaceutical firm dedicated to the development and commercialization of therapeutic solutions for individuals suffering from rare genetic epilepsies and other seizure-related conditions. The company's primary commercialized product is ZTALMY, an oral suspension specifically designed to manage seizures associated with cyclin-dependent kinase-like 5 deficiency disorder (CDD). This medication is prescribed for both adult and pediatric patient populations, suitable for use in acute and chronic care settings, and can be administered either in-patient or by the patient themselves. ZTALMY exerts its effect by targeting synaptic and extrasynaptic GABAA receptors, a mechanism that also suggests potential anticonvulsant, antidepressant, and anxiolytic benefits. Beyond ZTALMY, Marinus is actively progressing ganaxolone through development, an investigational therapy aimed at various genetic epileptic conditions such as PCDH19-related epilepsy, tuberous sclerosis complex, and Lennox-Gastaut Syndrome, with additional exploration for depressive disorders. The company maintains strategic alliances, including licensing agreements with Purdue Neuroscience Company and CyDex Pharmaceuticals, Inc., as well as a collaborative partnership with Orion Corporation. Marinus Pharmaceuticals was established in 2003 and operates from its corporate headquarters in Radnor, Pennsylvania.
주가
$0.55
마지막 동기화: 2025-02-11
시가총액
$28.90M
변동 (1일)
0.00%
변동 (1년)
0.00%
국가
US
거래 Marinus Pharmaceuticals, Inc. (MRNS)

카테고리

Marinus Pharmaceuticals, Inc. (MRNS)의 EPS
September 2024 기준 EPS TTM: $-2.47
Marinus Pharmaceuticals, Inc.의 최신 재무 보고서와 주가에 따르면, 현재 EPS (TTM)는 $-2.47입니다. 2022년 말에는 회사의 EPS가 $-0.51였으며, 이는 2021년의 EPS $-2.77와 감소입니다.
Marinus Pharmaceuticals, Inc.의 EPS 기록 (2012 ~ 2026)
매년 말의 EPS
연도 EPS 변화
2026 (TTM) $-2.47 -6.08%
2023 $-2.63 415.69%
2022 $-0.51 -81.59%
2021 $-2.77 13.52%
2020 $-2.44 -38.23%
2019 $-3.95 10.03%
2018 $-3.59 11.84%
2017 $-3.21 -45.41%
2016 $-5.88 -11.71%
2015 $-6.66 -5.40%
2014 $-7.04 169.73%
2013 $-2.61 272.86%
2012 $-0.70 0.00%
유사 기업 또는 경쟁사의 EPS
회사 EPS EPS 차이 국가
$17.32 -801.21%
US
$-7.98 223.08%
US
$27.74 -1,223.08%
NL
$2.98 -220.65%
AU
- -
CH